The core identified targets of aripiprazole include MAPK3 (mitogen-activated protein kinase 3), PPARG (peroxisome proliferator-activated receptor gamma), the D2 receptor, and ESR1 (estrogen receptor 1), providing new insights into the mechanisms of this drug in schizophrenia treatment. Here, MAPK3 is linked to schizophrenia.